Vanguard Group
AMLX icon

Vanguard Group’s Amylyx Pharmaceuticals AMLX Stock Holding History

Vanguard Group’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$70.1M Buy
5,804,912
+531,162
+10% +$7.21M ﹤0.01% 2002
2025
Q3 		$71.7M Buy
5,273,750
+775,722
+17% +$7.3M ﹤0.01% 1991
2025
Q2 		$28.8M Buy
4,498,028
+381,516
+9% +$1.86M ﹤0.01% 2383
2025
Q1 		$14.6M Buy
4,116,512
+1,424,023
+53% +$5.07M ﹤0.01% 2646
2024
Q4 		$10.2M Sell
2,692,489
-397,156
-13% -$1.87M ﹤0.01% 2946
2024
Q3 		$10M Sell
3,089,645
-1,134,323
-27% -$2.55M ﹤0.01% 2961
2024
Q2 		$8.03M Sell
4,223,968
-1,124,171
-21% -$2.18M ﹤0.01% 3035
2024
Q1 		$15.2M Buy
5,348,139
+72,573
+1% +$949K ﹤0.01% 2728
2023
Q4 		$77.7M Buy
5,275,566
+225,486
+4% +$3.46M ﹤0.01% 1986
2023
Q3 		$92.5M Buy
5,050,080
+124,188
+3% +$2.63M ﹤0.01% 1848
2023
Q2 		$106M Buy
4,925,892
+178,551
+4% +$4.82M ﹤0.01% 1822
2023
Q1 		$139M Buy
4,747,341
+388,849
+9% +$13.5M ﹤0.01% 1644
2022
Q4 		$161M Buy
4,358,492
+844,136
+24% +$30M ﹤0.01% 1552
2022
Q3 		$98.9M Buy
3,514,356
+2,520,355
+254% +$62.9M ﹤0.01% 1790
2022
Q2 		$19.1M Buy
994,001
+1,813
+0.2% +$21.5K ﹤0.01% 2656
2022
Q1 		$12.8M Buy
+992,188
New +$22.4M ﹤0.01% 3024

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Vanguard Group's AMLX Position: Q4 2025 in Review

Vanguard Group increased its Amylyx Pharmaceuticals (AMLX) stake by 10% in Q4 2025, buying an estimated $7.21M and bringing the position to 5,804,912 shares worth $70.1M. The position accounts for ﹤0.01% of the portfolio, ranked #2002.

Vanguard Group first reported a position in AMLX in Q1 2022 and has held it in 16 quarters since. The position peaked at $161M in Q4 2022. 179 funds tracked by Wall St. Rank hold AMLX as of Q4 2025.

  • Vanguard Group held 5,804,912 shares of Amylyx Pharmaceuticals worth $70.1M as of Q4 2025.
  • Vanguard Group bought 531,162 Amylyx Pharmaceuticals shares in Q4 2025, an estimated $7.21M.
  • Amylyx Pharmaceuticals made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #2002 holding.
  • Vanguard Group first reported a position in Amylyx Pharmaceuticals in Q1 2022 and has held it in 16 quarters since.
  • Vanguard Group's Amylyx Pharmaceuticals position peaked at $161M in Q4 2022.
  • 179 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.